Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2007

01-08-2007 | Original Paper

The burden-of-illness study on osteoporosis in the Slovenian female population

Authors: Biljana Dzajkovska, Albert I. Wertheimer, Ales Mrhar

Published in: International Journal of Clinical Pharmacy | Issue 4/2007

Login to get access

Abstract

Study objective

This burden-of-illness study on osteoporosis was performed with the main goal to estimate the economic implications of osteoporosis for the Slovenian healthcare system.

Methods

A variety of sources was used to quantify the utilization of resources in 2003, and the appropriate unit costs were assigned to the identified resources.

Main outcome measures

The study included all direct and indirect costs that arise from treatment of osteoporosis and consequent hip, spine and wrist fractures in total Slovene postmenopausal population in 2003.

Results

We estimated the total burden of postmenopausal osteoporosis in Slovenia for 2003 to be over SIT 7.55 billion (approximately €31.5 million); among that, 45% or SIT 3.39 billion (€14.2 million) belong to drug expenditures for osteoporosis treatment and prevention; 29% or SIT 2.2 billion (€9.2 million) include indirect costs for osteoporosis morbidity and mortality, and 26% or SIT 1.95 billion (€8.1 million) belong to direct costs for treatment, hospitalization, and rehabilitation of osteoporotic fractures. Total costs on osteoporotic fractures were however subject to an approximation due to the expert panel-based estimate of proportion of osteoporosis-caused fractures and the limited data on resource utilization for fracture treatment.

Conclusion

Osteoporosis is a costly disease with a significant burden to society and needs to be viewed as an important problem with a complex long-term impact.
Literature
1.
go back to reference WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994) World Health Organization Technical Report Series 843:5–6 WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994) World Health Organization Technical Report Series 843:5–6
2.
go back to reference Sedrine W, Radican L, Reginster J-Y On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center. Rheumatology 2001;40:7–14PubMedCrossRef Sedrine W, Radican L, Reginster J-Y On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center. Rheumatology 2001;40:7–14PubMedCrossRef
3.
go back to reference Morrison A, Wertheimer AI Types of Pharmacoeconomic Evaluation. In: Morrison A, Wertheimer AI, editors. Pharmacoeconomics. A primer for the pharmaceutical industry. Philadelphia: Temple University; 2002 Morrison A, Wertheimer AI Types of Pharmacoeconomic Evaluation. In: Morrison A, Wertheimer AI, editors. Pharmacoeconomics. A primer for the pharmaceutical industry. Philadelphia: Temple University; 2002
4.
go back to reference National Osteoporosis Foundation Status Report. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis International 1998; 8(S4):S1–S88 National Osteoporosis Foundation Status Report. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis International 1998; 8(S4):S1–S88
5.
go back to reference Ray N, Chan J, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997;12(1):24–35PubMedCrossRef Ray N, Chan J, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997;12(1):24–35PubMedCrossRef
6.
go back to reference Max W, Sinnot P, Kao C et al. The burden of osteoporosis in California, 1998. Osteoporosis International 2002;13:493–500PubMedCrossRef Max W, Sinnot P, Kao C et al. The burden of osteoporosis in California, 1998. Osteoporosis International 2002;13:493–500PubMedCrossRef
7.
go back to reference Dolan P, Torgerson DJ The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis International 1998;8:611–617PubMedCrossRef Dolan P, Torgerson DJ The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis International 1998;8:611–617PubMedCrossRef
8.
go back to reference Lane A Direct costs of osteoporosis for New Zealand women. PharmacoEconomics 1996;9(3):231–245PubMed Lane A Direct costs of osteoporosis for New Zealand women. PharmacoEconomics 1996;9(3):231–245PubMed
9.
go back to reference Rosner A, Grima D, Torrance G et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14(5):559–573PubMedCrossRef Rosner A, Grima D, Torrance G et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14(5):559–573PubMedCrossRef
10.
go back to reference IVZ. Ambulantno predpisovanje zdravil v Sloveniji po ATC klasifikaciji v letu; 2003. Available via <http://www.ivz.si> IVZ. Ambulantno predpisovanje zdravil v Sloveniji po ATC klasifikaciji v letu; 2003. Available via <http://​www.​ivz.​si>
11.
go back to reference Inštitut za varovanje zdravja Republike Slovenije: Zdravstveni statistični letopis; 2003 Inštitut za varovanje zdravja Republike Slovenije: Zdravstveni statistični letopis; 2003
12.
go back to reference Melton III L, Thamer M, Ray N et al. Fractures attributable to osteoporosis: report from the national osteoporosis foundation. Journal of Bone and Mineral Research 1997;12(1):16–23PubMedCrossRef Melton III L, Thamer M, Ray N et al. Fractures attributable to osteoporosis: report from the national osteoporosis foundation. Journal of Bone and Mineral Research 1997;12(1):16–23PubMedCrossRef
14.
go back to reference Ferk J Osteoporotični zlomi kolka, zapestja in hrbteničnega vretenca ter stroški zdravljenja Zdravniški Vestnik 2002;71:41–44 Ferk J Osteoporotični zlomi kolka, zapestja in hrbteničnega vretenca ter stroški zdravljenja Zdravniški Vestnik 2002;71:41–44
15.
go back to reference Koopmanschap AM, Rutten FH A practical guide for calculating indirect costs of disease. PharmacoEconomics 1996;10(5):460–466PubMedCrossRef Koopmanschap AM, Rutten FH A practical guide for calculating indirect costs of disease. PharmacoEconomics 1996;10(5):460–466PubMedCrossRef
18.
go back to reference De Laet C, Van Hout B, Burger H et al Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam study. Osteoporosis International 1999;10(1):66–72PubMedCrossRef De Laet C, Van Hout B, Burger H et al Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam study. Osteoporosis International 1999;10(1):66–72PubMedCrossRef
19.
go back to reference Vestergaard P, Rejnmark L, Mosekilde L Hip fracture prevention. Cost-effective strategies. Pharmacoeconomics 2001;19(5Pt1):449–468PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L Hip fracture prevention. Cost-effective strategies. Pharmacoeconomics 2001;19(5Pt1):449–468PubMedCrossRef
20.
go back to reference Kanis J, Oden A, Johnell O et al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International 2001;12:417–427PubMedCrossRef Kanis J, Oden A, Johnell O et al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International 2001;12:417–427PubMedCrossRef
21.
go back to reference Ankjaer-Jensen A, Johnell O Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis International 1996;6:265–275PubMedCrossRef Ankjaer-Jensen A, Johnell O Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis International 1996;6:265–275PubMedCrossRef
Metadata
Title
The burden-of-illness study on osteoporosis in the Slovenian female population
Authors
Biljana Dzajkovska
Albert I. Wertheimer
Ales Mrhar
Publication date
01-08-2007
Publisher
Kluwer Academic Publishers
Published in
International Journal of Clinical Pharmacy / Issue 4/2007
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9091-5

Other articles of this Issue 4/2007

International Journal of Clinical Pharmacy 4/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.